Dr Cesar Lopez Camacho

Dr César López-Camacho

Postdoctoral Researcher in the Neglected Tropical Diseases Programme led by Prof Arturo Reyes Sandoval, The Jenner Institute, University of Oxford

Dr López-Camacho holds a PhD in Molecular Biology from the University of Manchester, UK.  He pursued his postdoctoral fellowship in Molecular Biology and Fidelity of Gene Expression in Hematopoietic Lineages at the University of Massachusetts Medical School as well as at the University of Vermont College of Medicine, USA. He has worked with chimpanzee-adenovirus vaccines encoding an HIV-antigen as a visiting scientist at the Wistar Institute in Philadelphia PA, USA under the direction of Prof. Hildegund Ertl.

His research focuses in the development of viral-vectored vaccines against Dengue Virus (DENV), aiming to induce strong cellular immune responses (T-cell responses) against all four DENV serotypes.  Dr. Lopez-Camacho also is involved in the design and molecular cloning of other immunogens to be used as vaccines for Chagas, Malaria, and newly emerging diseases.  In this regard, he has co-supervised several undergraduates and summer placement students.  

Through NDM-Mexico, Dr Cesar López-Camacho has been in contact with several Mexican Institutions and has participated in different workshops held in Mexico and in the UK, with the objective to increase capacity building and expand collaborative projects related to infectious diseases. He is actively involved in projects that have already started in Mexico to address the immune responses of the DENV immunogen in patients that are or have been infected with Dengue.


Full PhD Scholarship by the Mexican Council of Science and Technology to pursue PhD studies at the University of Manchester, UK.


Medical Research Council, CiC Scheme “Tackling Dengue Virus: Addressing Protective Efficacy in a Dengue Challenge Model of a Novel Dengue Vaccine” Co-Applicant.

Email: cesar.lopez-camacho@ndm.ox.ac.uk

Key  Publications

“Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.” Nia Tatsis, Julie C. Fitzgerald, Arturo Reyes-Sandoval, Kimberly C. Harris-McCoy, Scott E. Hensley, Dongming Zhou, Shih-Wen Lin, Ang Bian, Zhi Quan Xiang, Amaya Iparraguirre, Cesar Lopez-Camacho, E. John Wherry, Hildegund C. J. Ertl, Blood. 2007 September 15; 110(6): 1916–1923.

“CBFβ and the Leukemogenic Fusion Protein CBFβ-SMMHC Associate with Mitotic Chromosomes to Epigenetically Regulate Ribosomal Gene Expression.” Cesar Lopez-Camacho, Andre J. van Wijnen, Jane B. Lian, Janet L. Stein, Gary S. Stein, J Cell Biochem. 2014 December; 115(12): 2155–2164. 

“Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Cesar Lopez-Camacho, Wensheng Deng, Jen-Yang Tang, Daniel Mendoza-Villanueva, Apolinar Maya-Mendoza, Dean A. Jackson, Paul Shore.” Proc Natl Acad Sci U S A. 2012 January 31; 109(5): 1524–1529. 

“Core Binding Factor β (CBFβ) is Retained in the Midbody During Cytokinesis.” Cesar Lopez-Camacho, Andre J. van Wijnen, Jane B. Lian, Janet L. Stein, Gary S. Stein, J Cell Physiol. 2014 October; 229(10): 1466–1474, J Cell Physiol. 2014 October; 229(10): 1466–1474.